BRPI0910232A2 - formas de sais inibidores do mtor - Google Patents
formas de sais inibidores do mtorInfo
- Publication number
- BRPI0910232A2 BRPI0910232A2 BRPI0910232A BRPI0910232A BRPI0910232A2 BR PI0910232 A2 BRPI0910232 A2 BR PI0910232A2 BR PI0910232 A BRPI0910232 A BR PI0910232A BR PI0910232 A BRPI0910232 A BR PI0910232A BR PI0910232 A2 BRPI0910232 A2 BR PI0910232A2
- Authority
- BR
- Brazil
- Prior art keywords
- salt forms
- inhibitor salt
- inhibitor
- forms
- salt
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003839 salts Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7006208P | 2008-03-19 | 2008-03-19 | |
| PCT/US2009/037505 WO2009117482A1 (en) | 2008-03-19 | 2009-03-18 | Mtor inhibitor salt forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0910232A2 true BRPI0910232A2 (pt) | 2015-09-29 |
Family
ID=40597405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0910232A BRPI0910232A2 (pt) | 2008-03-19 | 2009-03-18 | formas de sais inibidores do mtor |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8557814B2 (pt) |
| EP (1) | EP2276763A1 (pt) |
| JP (1) | JP2011515410A (pt) |
| KR (1) | KR20110017845A (pt) |
| CN (1) | CN101977912A (pt) |
| AU (1) | AU2009225614A1 (pt) |
| BR (1) | BRPI0910232A2 (pt) |
| CA (1) | CA2716924A1 (pt) |
| EA (1) | EA018144B1 (pt) |
| MX (1) | MX2010010300A (pt) |
| WO (1) | WO2009117482A1 (pt) |
| ZA (1) | ZA201006641B (pt) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2365869T3 (es) * | 2005-11-17 | 2011-10-11 | OSI Pharmaceuticals, LLC | COMPUESTOS BICÍCLICOS FUSIONADOS INHIBIDORES DE LA mTOR. |
| US20090274698A1 (en) * | 2007-07-06 | 2009-11-05 | Shripad Bhagwat | Combination anti-cancer therapy |
| EP2276763A1 (en) | 2008-03-19 | 2011-01-26 | OSI Pharmaceuticals, Inc. | Mtor inhibitor salt forms |
| WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
| NZ599830A (en) | 2009-11-05 | 2014-08-29 | Rhizen Pharmaceuticals Sa | Novel kinase modulators |
| EP2544672A1 (en) | 2010-03-09 | 2013-01-16 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| KR101548443B1 (ko) | 2011-02-23 | 2015-08-28 | 화이자 인코포레이티드 | 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진 |
| PH12013502240B1 (en) | 2011-05-04 | 2018-06-27 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of protein kinase |
| WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| RS56494B1 (sr) | 2012-07-04 | 2018-01-31 | Rhizen Pharmaceuticals S A | Selektivni inhibitori pi3k delta |
| EP3021849B1 (en) * | 2013-07-16 | 2019-10-09 | Dr. Reddy's Laboratories Ltd. | Novel crystalline forms of pemetrexed tromethamine salts |
| KR102497273B1 (ko) | 2014-03-06 | 2023-02-07 | 피티씨 테라퓨틱스, 인크. | 1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염 |
| US9987241B2 (en) | 2014-09-25 | 2018-06-05 | The Board Of Regents Of The University Of Oklahoma | Enzyme conjugate and prodrug cancer therapy |
| EP3209665B1 (en) | 2014-10-22 | 2019-08-14 | Bristol-Myers Squibb Company | Substituted pyrrolotriazine amine compounds as pi3k inhibitors |
| ES2807785T3 (es) | 2014-10-22 | 2021-02-24 | Bristol Myers Squibb Co | Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| KR102483020B1 (ko) | 2016-03-28 | 2023-01-04 | 인사이트 코포레이션 | Tam 저해제로서의 피롤로트리아진 화합물 |
| US11446365B2 (en) | 2017-08-09 | 2022-09-20 | The Board Of Regents Of The University Of Oklahoma | Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same |
| FR3075794A1 (fr) | 2017-12-21 | 2019-06-28 | Galderma Research & Development | Nouveaux composes inhibiteurs de mtor |
| FR3075795A1 (fr) | 2017-12-21 | 2019-06-28 | Galderma Research & Development | Nouveaux composes inhibiteurs de mtor |
| JOP20210147A1 (ar) * | 2018-12-21 | 2023-01-30 | Les Laboratoires Servier Sas | صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه |
| GB202415232D0 (en) | 2024-10-16 | 2024-11-27 | Nacamed As | Composition |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869485A (en) * | 1994-09-29 | 1999-02-09 | Novartis Finance Corp. | Pyrrolo 2,3-d!pyrimidines and their use |
| TR199902301T2 (xx) * | 1997-03-19 | 1999-12-21 | Basf Aktiengesellschaft | Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�. |
| US7863444B2 (en) * | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| US6383790B1 (en) * | 1999-01-11 | 2002-05-07 | Princeton University | High affinity protein kinase inhibitors |
| US6921763B2 (en) * | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| AU2002333524A1 (en) * | 2001-09-11 | 2003-03-24 | Glaxosmithkline K.K. | Furo-and thienopyrimidine derivatives as angiogenesis inhibitors |
| UA83509C2 (en) * | 2003-10-15 | 2008-07-25 | Оси Фармасьютикалз, Инк. | Imidazopyrazines as tyrosine kinase inhibitors |
| EP1687321A1 (en) * | 2003-10-27 | 2006-08-09 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
| CA2546192C (en) * | 2003-11-17 | 2010-04-06 | Pfizer Products Inc. | Pyrrolopyrimidine compounds useful in treatment of cancer |
| EP2168968B1 (en) * | 2004-04-02 | 2017-08-23 | OSI Pharmaceuticals, LLC | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| TW200613306A (en) * | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
| EP1831225A2 (en) * | 2004-11-19 | 2007-09-12 | The Regents of the University of California | Anti-inflammatory pyrazolopyrimidines |
| ES2365869T3 (es) * | 2005-11-17 | 2011-10-11 | OSI Pharmaceuticals, LLC | COMPUESTOS BICÍCLICOS FUSIONADOS INHIBIDORES DE LA mTOR. |
| AR057960A1 (es) * | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
| ES2545907T3 (es) * | 2005-12-29 | 2015-09-16 | Abbvie Inc. | Inhibidores de proteína quinasa |
| TW200738725A (en) * | 2006-01-25 | 2007-10-16 | Osi Pharm Inc | Unsaturated mTOR inhibitors |
| EP1996193A2 (en) * | 2006-03-13 | 2008-12-03 | OSI Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
| US20100273776A1 (en) | 2006-03-29 | 2010-10-28 | FOLDRx PHARMACEUTICALS, INC | Inhibition of alpha-synuclein toxicity |
| WO2007114926A2 (en) * | 2006-04-04 | 2007-10-11 | The Regents Of The University Of California | Kinase antagonists |
| DE102006016426A1 (de) | 2006-04-07 | 2007-10-11 | Merck Patent Gmbh | Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren |
| US20090274698A1 (en) * | 2007-07-06 | 2009-11-05 | Shripad Bhagwat | Combination anti-cancer therapy |
| EP2173338A1 (en) * | 2007-07-06 | 2010-04-14 | OSI Pharmaceuticals, Inc. | Combination anti-cancer therapy |
| MX2010004074A (es) * | 2007-10-15 | 2010-07-02 | Astrazeneca Ab | Combinacion 059. |
| EP2276763A1 (en) | 2008-03-19 | 2011-01-26 | OSI Pharmaceuticals, Inc. | Mtor inhibitor salt forms |
| BR112012000494A2 (pt) | 2009-07-09 | 2015-09-15 | Osi Pharmaceuticals Llc | processo para 3-amino-5-oxo-4,5-di-hidro-[1,2,4]triazinas substituídas |
| EP2459191A1 (en) | 2009-07-31 | 2012-06-06 | OSI Pharmaceuticals, LLC | Mtor inhibitor and angiogenesis inhibitor combination therapy |
-
2009
- 2009-03-18 EP EP09722933A patent/EP2276763A1/en not_active Withdrawn
- 2009-03-18 WO PCT/US2009/037505 patent/WO2009117482A1/en not_active Ceased
- 2009-03-18 US US12/922,928 patent/US8557814B2/en not_active Expired - Fee Related
- 2009-03-18 KR KR1020107021794A patent/KR20110017845A/ko not_active Withdrawn
- 2009-03-18 CA CA2716924A patent/CA2716924A1/en not_active Abandoned
- 2009-03-18 CN CN2009801096507A patent/CN101977912A/zh active Pending
- 2009-03-18 EA EA201071099A patent/EA018144B1/ru not_active IP Right Cessation
- 2009-03-18 JP JP2011500920A patent/JP2011515410A/ja active Pending
- 2009-03-18 BR BRPI0910232A patent/BRPI0910232A2/pt not_active IP Right Cessation
- 2009-03-18 AU AU2009225614A patent/AU2009225614A1/en not_active Abandoned
- 2009-03-18 MX MX2010010300A patent/MX2010010300A/es not_active Application Discontinuation
-
2010
- 2010-09-16 ZA ZA2010/06641A patent/ZA201006641B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110017845A (ko) | 2011-02-22 |
| AU2009225614A1 (en) | 2009-09-24 |
| WO2009117482A8 (en) | 2010-04-08 |
| JP2011515410A (ja) | 2011-05-19 |
| WO2009117482A1 (en) | 2009-09-24 |
| CA2716924A1 (en) | 2009-09-24 |
| MX2010010300A (es) | 2010-10-26 |
| ZA201006641B (en) | 2011-05-25 |
| EP2276763A1 (en) | 2011-01-26 |
| US20110015197A1 (en) | 2011-01-20 |
| EA201071099A1 (ru) | 2011-02-28 |
| CN101977912A (zh) | 2011-02-16 |
| EA018144B1 (ru) | 2013-05-30 |
| US8557814B2 (en) | 2013-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0910232A2 (pt) | formas de sais inibidores do mtor | |
| CY2020023I1 (el) | Αναστολεiς βητα-λακταμασων | |
| FIC20200046I1 (fi) | Alpelisibi tai sen suola | |
| BRPI0922466A2 (pt) | sais | |
| BRPI0917808A2 (pt) | inibidores de cmet | |
| EP2305306A4 (en) | NEURO INVASION INHIBITOR | |
| BRPI0906764A2 (pt) | Processos | |
| EP2266026A4 (en) | EFFICIENT DETERMINIST MULTIPLE PROCESSING | |
| BRPI0911175A2 (pt) | conjuntos de válvula | |
| BRPI0821868A2 (pt) | Grânulo | |
| BRPI0908115A2 (pt) | torneira | |
| BRPI0924163A2 (pt) | kit de limpeza de arma de fogo | |
| BRPI0919591A2 (pt) | válvula magnética | |
| BRPI0918564A2 (pt) | inibidores | |
| BRPI0914781A2 (pt) | Microbiocidas | |
| BRPI0908513A2 (pt) | válvula | |
| BRPI0911625A2 (pt) | Métodos | |
| EP2317192A4 (en) | MAGNETIC VALVE | |
| FR2914943B1 (fr) | Aube de soufflante | |
| BRPI0821901A2 (pt) | Válvula homogeneizadora | |
| BRPI0909106A2 (pt) | Método herbicida | |
| BRPI0918966A2 (pt) | inibidores de protease | |
| BRPI0912564A2 (pt) | inibidores de jnk | |
| DE602007002163D1 (de) | Weichspülmittel | |
| IT1394067B1 (it) | Valvola |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |